Efficacy and Safety of Low-Dose Cyclosporine with Everolimus and Steroids in de novo Heart Transplant Patients: A Multicentre, Randomized Trial

Table 2

Immunosuppression. Continuous variables are shown as mean ± SD.

	RD CsA (𝑛=99)	ST CsA (𝑛=100)
Everolimus dose (mg/day)
Month 1	1.3±0.5	1.4±0.6
Month 6	1.4±0.6	1.3±0.5
Everolimus trough concentration (ng/mL)
Month 1	5.8±3.6	5.8±2.5
Month 6	4.8±1.7	5.3±2.3
Cyclosporine dose (mg/kg/day)
Month 1	3.8±1.3	4.0±1.4
Month 6	2.5±1.0	2.8±0.8
Cyclosporine trough concentration (ng/mL)
Months 1-2	195±78	209±87
Month 6	120±63	154±68
Cyclosporine C2 concentration (ng/mL)
Months 1-2	742±272	693±244
Month 6	566±278	707±284
Steroid dose^a	0.50±1.40	0.32±0.25
Induction therapy
Antithymocyte globulin	60 (60.6%)	61 (61.0%)
Interleukin-2 receptor antagonist	21 (21.2%)	20 (20.0%)

^a Mean dose during Months 0–6.